Natural Capsules' consolidated record has turned sharply negative: a ₹24.66 crore loss in FY26, a subsidiary whose losses are indicated by the gap between consolidated and standalone PAT, and receivables that have stretched to 139 days against a stated 0-90 day credit period. The standalone entity remains profitable, but the consolidated picture is one of negative returns, near-zero cash, and a rating that has been downgraded twice in nine months.
Key findings
- Consolidated loss of ₹24.66 crore wipes out standalone profit as the API subsidiary burns cash
Major- Consolidated PAT fell from ₹5.55 crore in FY24 to ₹0.62 crore in FY25 and to ₹-24.66 crore in FY26, while cumulative operating cash flow over nine years covered only 60% of cumulative EBITDA. Management acknowledged a “near zero cash balance” with fundraising options under evaluation. - Trade receivables stretch to 139 days against a 0-90 day credit period
Major- Receivable days have exceeded the stated 0-90 day credit period for four consecutive years, reaching 139 days in FY26 on an outstanding of ₹67.48 crore (gross, unsecured considered good). In FY23, the company disclosed that balance confirmations for trade receivables had been circulated but receipt and reconciliation were in process. - Material subsidiary Natural Biogenex has repeatedly missed its timeline, and the parent's stake fell to 69.23%
Major- The API project was originally expected to begin trial production by Q1 FY2022-23 and achieved commercial batches only in FY25. Consolidated PAT of ₹-24.66 crore versus standalone PAT of ₹11.21 crore indicates losses at the subsidiary level, though the difference also reflects other consolidation adjustments and the second subsidiary [SQL]. The parent's ownership in Natural Biogenex declined to 69.23% by FY26. - The financial guarantee to Natural Biogenex has grown from ₹48 crore to ₹74.41 crore, with a PE claw-back clause tied to FY29
Major- The outstanding financial guarantee to banks for subsidiary loans rose from ₹48 crore in FY23 to ₹74.41 crore in FY26, with future cash outflows determinable only on receipt of judgments or decisions. Management confirmed a claw-back clause exists in the PE investor's shareholders agreement tied to FY29 targets, though stated “at this point of time, there is no discussion on that”. - ICRA downgraded the rating twice in nine months to BB+, while standalone borrowings of ₹58 crore mask ₹56 crore of subsidiary debt
Major- ICRA downgraded the long-term rating from BBB (Stable) to BB+ (Stable) between November 2024 and August 2025, citing subdued subsidiary performance. Consolidated borrowings stood at ₹114 crore against standalone borrowings of ₹58.13 crore, and shareholders have authorised mortgaging the company's properties to secure subsidiary borrowings up to ₹200 crore. - Promoter family dominates the board, with remuneration repeatedly revised upward and low shareholder turnout
Minor- Five of eight directors are related inter se, and at the 32nd AGM all five resolutions, including re-appointment of promoter directors with revised remuneration, received 100% of votes polled in favour. Only 51.39% of outstanding shares were polled. The company cycled through three company secretaries between May 2025 and May 2026, and an 85-year-old promoter-director is proposed for re-appointment as Whole Time Director. - Recurring secretarial compliance lapses include late ROC filings, but no capital-market penalties have been imposed
Minor- The Secretarial Auditor reported delays in filing e-forms with additional fees at both the company and its subsidiary in FY26 and FY24, and the company previously compounded a default for non-appointment of a whole-time Company Secretary for the period 01/04/2014 to 25/03/2015. The company stated that no penalties or strictures were imposed by Stock Exchanges, SEBI, or any statutory authority related to Capital Markets during the last three years.
What to watch
- Fundraising outcome. Management stated in the Q4 FY26 call that it is evaluating a preferential allotment or rights issue.
- API clean-room capex. Completion of the additional ₹25-30 crore capex and associated fundraising, as discussed in the Q4 FY26 call.
- Financial guarantee crystallisation. The ₹74.41 crore guarantee to Natural Biogenex, contingent on judgments or decisions at pending forums, as disclosed in the FY26 Annual Report.
- PE claw-back clause. The clause under the Natural Biogenex shareholders agreement tied to FY29 targets, as stated by management in March 2026.
Bottom line: This is a record of a standalone business that still generates profit, but whose consolidated position has been consumed by a subsidiary that has missed every timeline, diluted the parent's stake, and now requires fresh capital to continue. The receivables book and the financial guarantee are the two lines that connect the listed entity's balance sheet to that subsidiary's performance. Watch the fundraising outcome and the FY29 PE claw-back clause.